MarginsXMarginsX
Home › Markets › Health Care › PBH

Prestige Consumer Healthcare Inc. (PBH)

PBH trades on NYSE in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$48.00
+3.92% on the day
Market cap
$2.3B
Mid cap
Revenue · 2025
$1.1B
-4.3% on 2024
Net income · 2025
$190.3M
17.5% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2026-03-31, https://www.sec.gov/Archives/edgar/data/1295947/000129594726000016/0001295947-26-000016-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2026-03-31.

Profile

FieldValue
TickerPBH on NYSE
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO year2005
SEC CIK0001295947
SEC industry codePharmaceutical Preparations

Financials · 2025

LineValue
Revenue$1.1B
Net income$190.3M
Operating income$309.4M
Net margin17.5%
Operating margin28.4%
Revenue growth-4.3%
Cash$63.9M
Total assets$3.5B
P/E (computed)12.0×
P/S (computed)2.1×

Warning signs

Cash runway
Cash-flow positive
$46.5M cash at September 30, 2026
Share count, 1 year
-1.4%
2025-10-31 to 2026-10-30 · -4.5% over 3 years
Going-concern doubt
No
10-Q filed November 5, 2026
Insider net buying, 12 months
-$424K
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-11-05
Cash and burn$46.5M cash; operating cash flow $57.4M a quarter.Report 2026-09-30
Shares outstanding47,397,106 (2026-10-30); 48,084,010 a year earlier; 49,618,585 three years earlier.Cover page 2026-10-30
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 0 424B5 takedownsNone on EDGAR
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorPricewaterhouseCoopers LLP, Stamford, Connecticut, United StatesPCAOB Form AP 2026-05-28
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $424K on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q2 2027
2026-09-30
$336.3M$25.3M$37.9M$46.5M$2.1B$1.2B10-Q 2026-11-05
Q1 2027
2026-06-30
$265.7M$29.2M$70.8M$89.1M$2.0B$1.1B10-Q 2026-08-06
Q4 2026
2026-03-31
$281.6M$53.9M$42.8M$63.9M$994.0M$1.1B10-K 2026-05-14
Q3 2026
2025-12-31
$283.4M$46.7M$78.3M$62.4M$1.0B$1.1B10-Q 2026-02-05
Q2 2026
2025-09-30
$274.1M$42.2M$57.5M$119.1M$993.1M$1.1B10-Q 2026-11-05
Q1 2026
2025-06-30
$249.5M$47.5M$79.0M$139.5M$992.7M$1.1B10-Q 2026-08-06
Q4 2025
2025-03-31
$296.5M$50.1M$61.8M$97.9M$992.4M$1.1B10-K 2026-05-14
Q3 2025
2024-12-31
$290.3M$61.0M$65.1M$50.9M$992.0M$1.1B10-Q 2026-02-05

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B32012-07-13
Latest annual report10-K2026-05-14
Latest quarterly / interim10-Q2026-11-05
Latest current report8-K2026-11-05
Latest proxyDEF 14A2026-06-29

Source: SEC EDGAR submissions feed, 1,002 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week+7.5%
1 month-4.8%
3 months-10.0%
Year to date-25.1%
1 year-23.0%
From 52-week high-34.2%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
PHVSPharvaris N.V.$32.44-2.76%$2.3B
LKFTLakefront Biotherapeutics$34.79+2.38%$2.3B
PRGOPerrigo Company plc$16.18-0.37%$2.2B
NAMSNewAmsterdam Pharma Company N.V.$19.46-3.38%$2.3B
RCUSArcus Biosciences Inc.$16.86-3.27%$2.4B
PVLAPalvella Therapeutics Inc.$144.60-5.17%$2.1B
BHVNBiohaven Ltd. Common Shares$13.80-0.14%$2.1B
IMNMImmunome Inc.$17.61-6.18%$2.1B

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier